Menactra Injection

Manectra Injection Vial: Comprehensive Protection Against Meningococcal Disease

The Manectra Injection Vial is a vital vaccine designed to provide immunity against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Manufactured by Sanofi Pasteur, a global leader in vaccine development, this vaccine plays a crucial role in safeguarding public health, especially among adolescents and young adults.

Key Features:

• Broad-Spectrum Protection: Targets four major serogroups (A, C, Y, W-135) responsible for the majority of meningococcal infections.
• Conjugate Vaccine Technology: Utilizes a conjugate formulation to enhance immune response and provide longer-lasting immunity compared to polysaccharide vaccines.
• Established Manufacturer: Developed by Sanofi Pasteur, ensuring adherence to stringent quality and safety standards.

Uses and Indications:

Manectra is primarily indicated for active immunization against invasive meningococcal disease in individuals aged 9 months through 55 years. It is especially recommended for:

• Adolescents and Young Adults: Age groups with a higher incidence of meningococcal disease.
• Individuals with Certain Medical Conditions: Such as asplenia or complement component deficiencies.
• Travelers: Those traveling to regions where meningococcal disease is endemic or during outbreaks.

Dosage and Administration:

• Children (9-23 months): Two doses of 0.5 mL each, administered three months apart.
• Individuals (2-55 years): A single 0.5 mL dose.

The vaccine is administered intramuscularly, preferably in the deltoid muscle. It is essential to follow the vaccination schedule recommended by healthcare professionals to ensure optimal protection.

Side Effects:

Common side effects are generally mild and temporary, including:

• Injection Site Reactions: Redness, swelling, or pain at the injection site.
• Systemic Reactions: Fever, headache, fatigue, or muscle pain.

Serious allergic reactions are rare but require immediate medical attention. It is important to discuss any concerns or pre-existing conditions with a healthcare provider before receiving the vaccine.

Frequently Asked Questions:

1. What is the price of Manectra Injection Vial in Pakistan?Prices may vary depending on the pharmacy and location. For current pricing, it is advisable to contact local pharmacies or visit reputable online medical stores such as MedicineWalyDost.com.
2. Is Manectra suitable for infants under 9 months?No, Manectra is approved for use in individuals aged 9 months through 55 years. For infants younger than 9 months, consult a healthcare provider for appropriate vaccination options.
3. Can Manectra be administered with other vaccines?Yes, Manectra can be given concurrently with other vaccines; however, it should be administered at a different injection site. Always consult with a healthcare provider for personalized advice.
4. What should I do if I miss a scheduled dose?If a dose is missed, contact your healthcare provider to reschedule as soon as possible to maintain optimal protection.
5. Are booster doses necessary?Booster doses may be recommended for individuals at continued risk of meningococcal disease. Consult with a healthcare provider to determine if a booster is needed based on individual risk factors.

Manectra Injection Vial, Meningococcal Vaccine, Sanofi Pasteur, Meningitis Prevention, Meningococcal Disease Immunization, Vaccine Price in Pakistan, MedicineWalyDost.com

Note: This information is intended for educational purposes and should not replace professional medical advice. Always consult a healthcare provider for personalized guidance.